Anti-CD11a monoclonal antibody
Latest Information Update: 25 Sep 2021
Price :
$50 *
At a glance
- Originator Nonindustrial source
- Class
- Mechanism of Action CD11a antigen antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bone marrow transplant rejection; Diabetes mellitus
Most Recent Events
- 12 Sep 2000 No-Development-Reported for Bone marrow transplant rejection in Japan (Unknown route)
- 12 Sep 2000 No-Development-Reported for Diabetes mellitus in Japan (Unknown route)
- 28 Aug 1996 Investigation in Bone marrow transplant rejection in Japan (Unknown route)